At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 36 target
Drug / intervention
Stereotactic Body Radiotherapyradiation
Likely dose
Not stated in record
Key inclusion· 5
- ✓Men >4 years from EBRT with biochemical failure per Phoenix definition, or >5 years if neo-adjuvant/adjuvant ADT also used
- ✓Recurrence localized to <1 lobe of prostate on both PSMA and multiparametric MRI (≤cT2a)
- ✓Recurrence must be biopsy-proven, with positive biopsies limited to PET and MRI suspicious region
- ✓Life expectancy at least 10 years from time of SBRT
Key exclusion· 4
- ✕Recurrence in immediate proximity to rectum (unless able to have hydrogel)
- ✕Grade 3 or higher toxicity from previous EBRT
- ✕Contraindicated for fiducial insertion
- ✕Gleason Score 8, 9, or 10 disease previously (relative—consider if decent disease-free interval)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate
In Brief
A clinical study evaluating Stereotactic Body Radiotherapy for Locally Recurrent Prostate Cancer. Currently recruiting, targeting 36 participants across 1 site.
Detailed Summary
To examine the feasibility, safety and toxicity of focal stereotactic radiation treatment (SBRT) for locally recurrent prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Recurrent Prostate Cancer
CountriesAustralia
Timeline
N/ARecruiting
20172018201920202021202220232024202520262027
First PostedMar 2017
Enrollment StartApr 2017
TodayJul 2026
Primary CompletionMar 2027
First PostedMar 8, 2017
Enrollment StartApr 24, 2017
Primary CompletionMar 31, 2027
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 9.3 years agoPrimary completion in 9 months
Interventions
Stereotactic Body Radiotherapyradiation
Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.